These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 27003409)
1. A Large Proportion of the Mexican Population Remained Susceptible to A(H1N1)pdm09 Infection One Year after the Emergence of 2009 Influenza Pandemic. Veguilla V; López-Gatell H; López-Martínez I; Aparicio-Antonio R; Barrera-Badillo G; Rojo-Medina J; Gross FL; Jefferson SN; Katz JM; Hernández-Ávila M; Alpuche-Aranda CM PLoS One; 2016; 11(3):e0150428. PubMed ID: 27003409 [TBL] [Abstract][Full Text] [Related]
2. Assessment of baseline age-specific antibody prevalence and incidence of infection to novel influenza A/H1N1 2009. Hardelid P; Andrews NJ; Hoschler K; Stanford E; Baguelin M; Waight PA; Zambon M; Miller E Health Technol Assess; 2010 Dec; 14(55):115-92. PubMed ID: 21208549 [TBL] [Abstract][Full Text] [Related]
3. Seroprevalence of Pandemic A(H1N1) pmd09 Virus Antibodies in Mexican Health Care Workers Before and After Vaccination. Aguilar-Madrid G; Castelán-Vega JA; Juárez-Pérez CA; Ribas-Aparicio RM; Estrada-García I; Baltierra-Jasso L; Cervantes-Servín N; Méndez-Ortega V; Haro-García LC; Sánchez-Román FR; Ortiz-Navarrete V; Fabila-Castillo LH; Magaña-Hernández A; Chávez-Negrete A; Salamanca-Gómez FA; Jiménez-Alberto A Arch Med Res; 2015 Feb; 46(2):154-63. PubMed ID: 25796508 [TBL] [Abstract][Full Text] [Related]
4. Rate of decline of antibody titers to pandemic influenza A (H1N1-2009) by hemagglutination inhibition and virus microneutralization assays in a cohort of seroconverting adults in Singapore. Hsu JP; Zhao X; Chen MI; Cook AR; Lee V; Lim WY; Tan L; Barr IG; Jiang L; Tan CL; Phoon MC; Cui L; Lin R; Leo YS; Chow VT BMC Infect Dis; 2014 Jul; 14():414. PubMed ID: 25066592 [TBL] [Abstract][Full Text] [Related]
5. Seroprevalence of antibody to influenza A(H1N1)pdm09 attributed to vaccination or infection, before and after the second (2010) pandemic wave in Australia. McVernon J; Laurie K; Faddy H; Irving D; Nolan T; Barr I; Kelso A Influenza Other Respir Viruses; 2014 Mar; 8(2):194-200. PubMed ID: 24382379 [TBL] [Abstract][Full Text] [Related]
6. Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine. Tete SM; Jul-Larsen Å; Rostami S; Lunde THF; Søland H; Krammer F; Cox RJ Vaccine; 2018 Apr; 36(16):2213-2219. PubMed ID: 29548607 [TBL] [Abstract][Full Text] [Related]
7. Infection with influenza A(H1N1)pdm09 during the first wave of the 2009 pandemic: Evidence from a longitudinal seroepidemiologic study in Dhaka, Bangladesh. Nasreen S; Rahman M; Hancock K; Katz JM; Goswami D; Sturm-Ramirez K; Holiday C; Jefferson S; Branch A; Wang D; Veguilla V; Widdowson MA; Fry AM; Brooks WA Influenza Other Respir Viruses; 2017 Sep; 11(5):394-398. PubMed ID: 28688210 [TBL] [Abstract][Full Text] [Related]
8. Influenza A(H1N1)pdm09 antibodies after pandemic and trivalent seasonal influenza vaccination as well as natural infection in November 2010 in Hamburg, Germany. Cramer J; Mac T; Hogan B; Stauga S; Eberhardt S; Wichmann O; Mertens T; Burchard G Euro Surveill; 2012 Jan; 17(2):. PubMed ID: 22264864 [TBL] [Abstract][Full Text] [Related]
9. Host immune response to A(H1N1)pdm09 vaccination and infection: a one-year prospective study on six cohorts of subjects. Liu W; Ma MJ; Tang F; He C; Zhang XA; Jiang LF; Xin DS; Hu CY; Looman C; Cao WC Vaccine; 2012 Jul; 30(32):4785-9. PubMed ID: 22633868 [TBL] [Abstract][Full Text] [Related]
10. Post-pandemic seroprevalence of 2009 pandemic influenza A (H1N1) virus in Shandong Province, China. Liu T; Li Z; Song S; Zhang S; Wang Y; Lin Y; Wang S; Wang X; Xu A; Bi Z Jpn J Infect Dis; 2012; 65(5):410-4. PubMed ID: 22996214 [TBL] [Abstract][Full Text] [Related]
11. Absence of cross-reactive antibodies to influenza A (H1N1) 2009 before and after vaccination with 2009 Southern Hemisphere seasonal trivalent influenza vaccine in children aged 6 months-9 years: a prospective study. McVernon J; Laurie K; Barr I; Kelso A; Skeljo M; Nolan T Influenza Other Respir Viruses; 2011 Jan; 5(1):7-11. PubMed ID: 21138535 [TBL] [Abstract][Full Text] [Related]
12. Estimating age-specific cumulative incidence for the 2009 influenza pandemic: a meta-analysis of A(H1N1)pdm09 serological studies from 19 countries. Van Kerkhove MD; Hirve S; Koukounari A; Mounts AW; Influenza Other Respir Viruses; 2013 Sep; 7(5):872-86. PubMed ID: 23331969 [TBL] [Abstract][Full Text] [Related]
13. The priming effect of previous natural pandemic H1N1 infection on the immunogenicity to subsequent 2010-2011 influenza vaccination in children: a prospective cohort study. Kang EK; Eun BW; Kim NH; Lim JS; Lee JA; Kim DH BMC Infect Dis; 2016 Aug; 16(1):438. PubMed ID: 27549626 [TBL] [Abstract][Full Text] [Related]
14. Impact of prior infection and repeated vaccination on post-vaccination antibody titers of the influenza A(H1N1)pdm09 strain in Taiwan schoolchildren: Implications for public health. Liu W; Lien YH; Lee PI; Chan TC; Wang LC; Yang CR; Ho MS; Chen JR; Ku CC; King CC Vaccine; 2022 May; 40(24):3402-3411. PubMed ID: 35525727 [TBL] [Abstract][Full Text] [Related]
15. [Seroprevalence of pandemic influenza A (H1N1)pdm09 in two regions in Morocco following the 2010-2011 influenza season]. El Rhaffouli H; El Boukhrissi F; Bajjou T; Laraqui A; Hilali F; Bahji M; El Harrak M; Lahlou Amine I Pathol Biol (Paris); 2013 Apr; 61(2):83-6. PubMed ID: 22728009 [TBL] [Abstract][Full Text] [Related]
16. Cross-reactive immunity against influenza viruses in children and adults following 2009 pandemic H1N1 infection. Ahmed MS; Jacques LC; Mahallawi W; Ferrara F; Temperton N; Upile N; Vaughan C; Sharma R; Beer H; Hoschler K; McNamara PS; Zhang Q Antiviral Res; 2015 Feb; 114():106-12. PubMed ID: 25513756 [TBL] [Abstract][Full Text] [Related]
17. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine. Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864 [TBL] [Abstract][Full Text] [Related]
18. Pandemic influenza A/H1N1 2009 antibodies in the metropolitan area of Buenos Aires in Argentina. Labato MI; Contrini MM; Lazzarini D; Campos AM; Gauna ML; Claros R; López EL; Savy VL; Luna CM Int J Infect Dis; 2014 Feb; 19():20-5. PubMed ID: 24211378 [TBL] [Abstract][Full Text] [Related]
19. Key points in evaluating immunogenicity of pandemic influenza vaccines: A lesson from immunogenicity studies of influenza A(H1N1)pdm09 vaccine. Ohfuji S; Kobayashi M; Ide Y; Egawa Y; Saito T; Kondo K; Ito K; Kase T; Maeda A; Fukushima W; Hirota Y Vaccine; 2017 Sep; 35(39):5303-5308. PubMed ID: 28784284 [TBL] [Abstract][Full Text] [Related]
20. Regional and age-specific patterns of pandemic H1N1 influenza virus seroprevalence inferred from vaccine clinical trials, August-October 2009. Tsai TF; Pedotti P; Hilbert A; Lindert K; Hohenboken M; Borkowski A; Groth N; da Silva LJ; Kyaw MH Euro Surveill; 2010 Jul; 15(30):. PubMed ID: 20684814 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]